MarketBeat
09 Aug 2026, 04:05 UTC · 1h ago
ResMed Q4 Earnings Call Highlights
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
09 Aug 2026, 04:05 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
ResMed has suspended new sales of Astral life-support devices during fiscal 2027, creating an estimated $75 million revenue headwind and a $0.15 EPS hit. — Direct revenue loss and earnings dilution stemming from a product safety-related sales suspension is a material negative catalyst.
-0.60The company forecasts fiscal 2027 non-GAAP EPS of $12.00 to $12.25, representing reported growth of 7% to 10% (or 12% to 14% on a core basis). — Solid double-digit core earnings growth guidance provides a predictable upward trajectory for valuation.
+0.40Data suggests patients on GLP-1 medicines are 11% more likely to begin PAP therapy and show higher long-term adherence than those on PAP alone. — Provides empirical evidence for a significant growth tailwind from the expanding GLP-1 market, countering fears that weight loss drugs might reduce sleep apnea demand.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Fourth-quarter non-GAAP EPS rose 16% to $2.95, and full-year free cash flow exceeded $1.6 billion. — Strong historical performance and cash generation support dividend sustainability and share repurchases.
+0.30ResMed expects non-GAAP gross margins to expand by a low-double-digit number of basis points in fiscal 2027 through productivity and pricing. — Margin expansion indicates operational efficiency and pricing power despite inflationary pressures on components and freight.
+0.20Which stocks this story touches
The company reported strong revenue and EPS growth, though gains are partially offset by the suspension of Astral sales and related provisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
MarketBeat
1h ago
